Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Superficial curettage plus imiquimod cream 5% in the treatment of nodular basal cell carcinoma showed more treatment failure at 5 years vs. surgical excision, according to a study.“Surgical excision ...